Physician profile
Anthony Granato
NPI 1508838202
$4,965.72
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,051 · 2020: $687 · 2021: $821 · 2022: $1,277 · 2023: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $986.94 | 2019-2022 | |
| Glaxosmithkline, LLC. | $971.11 | 2019-2023 | Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $538.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.82 | 2019-2022 | |
| Insmed, INC. | $316.06 | 2019-2023 | Arikayce |
| Mylan Specialty L.P. | $224.49 | 2019-2022 | |
| Genzyme Corporation | $148.65 | 2019-2022 | |
| Grifols USA, LLC | $131.38 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $120.90 | 2019-2022 | |
| Philips North America LLC | $107.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $106.94 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $82.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.87 | 2020-2023 | Aralast |
| Janssen Pharmaceuticals, INC | $73.81 | 2019-2022 | |
| Genentech USA, INC. | $73.31 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $71.93 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $71.27 | 2019-2022 | |
| Shire North American Group INC | $54.80 | 2019 | |
| Mallinckrodt Enterprises LLC | $54.56 | 2019 | |
| United Therapeutics Corporation | $43.63 | 2022 | |
| Amgen INC. | $40.24 | 2022 | |
| Baxter Healthcare | $37.99 | 2022 | |
| Inspire Medical Systems, INC. | $36.87 | 2023 | Inspire |
| Mallinckrodt Hospital Products INC. | $29.41 | 2022-2023 | Acthar |
| Merck Sharp & Dohme LLC | $25.49 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $24.83 | 2021 | |
| Vapotherm INC | $24.56 | 2019 | |
| Resmed Corp | $16.77 | 2020 | |
| Optinose US, INC. | $14.82 | 2019 | |
| Electromed, INC. | $14.60 | 2019 | |
| Pfizer INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Granato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.